# Creating Tomorrow's **KAMAN** Today

Q3 2020 Earnings Call Supplement November 5, 2020



#### FORWARD-LOOKING STATEMENTS

This presentation includes "forward looking statements" relating to the announced transactions and future operations of the Company, which can be identified by the use of words such as "will," "expect," "poise," "believe," "plans," "strategy," "prospects," "estimate," "project", "seek," "target," "anticipate," "intend," "future," "likely," "may," "should," "would," "could," and other words of similar meaning in connection with a discussion of future operating or financial performance or events. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These statements are based on assumptions currently believed to be valid but involve significant risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ from those expressed in the forward looking statements. Such risks and uncertainties include, among others, the ability to implement the anticipated business plans following closing and expenditures. Additional risks and uncertainties that could cause our actual results to differ from those expressed in the forward looking statements are identified in our reports filed with the SEC, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K, and our Current Reports on Form 8-K. The forward looking statements included in this presentation are made only as of the date of this presentation, and the Company does not undertake any obligation to update the forward looking statements to reflect subsequent events or circumstances.

#### **Non-GAAP Figures**

Management believes that the Non-GAAP financial measures (i.e. financial measures that are not computed in accordance with Generally Accepted Accounting Principles) identified by an asterisk (\*) used in this presentation or in other disclosures provide important perspectives into the Company's ongoing business performance. The Company does not intend for the information to be considered in isolation or as a substitute for the related GAAP measures. Other companies may define the measures differently. Reconciliations from GAAP measures to the Non-GAAP measures are presented herein.

ΚΔΜΔΙ

### Q3 2020 Overview



	<ul> <li>Net Sales up 17.1% over third quarter of 2019; Organic sales* up 6.7%</li> </ul>							
Financial	<ul> <li>Gross margins in excess of 30% and SG&amp;A controls improve profitability</li> </ul>							
Performance	<ul> <li>Adjusted EBITDA* of 16.6%, a 190 bps increase over prior year period</li> </ul>							
(from continuing operations)	<ul> <li>Adjusted diluted earnings per share* increased \$0.24 to \$0.70</li> </ul>							
	<ul> <li>Available cash on hand of \$152 million</li> </ul>							
	<ul> <li>Diversified product portfolio providing offset to continued weakness in commercial aviation</li> </ul>							
Key	<ul> <li>Delivering on cost savings with approximately \$42.5 million in annualized savings; Identified opportunities to deliver \$7.5 million in additional savings</li> </ul>							
Messages	<ul> <li>Maintained discipline in application of our COVID-19 policies and procedures</li> </ul>							
	<ul> <li>Strong balance sheet and significant capacity under our revolving credit facility</li> </ul>							

No debt maturities until 2024

### **Diversified Portfolio**

### KAMAN

Year-To-Date Sales up 14.4% to \$599.2 million; Organic Sales\* up 2.8%

Actual YTD Q3 2020 Sales By End Market




56% Defense



9% Medical



Commercial, Business & General Aviation Sales 27% of Total



<sup>(1)</sup> % totals are an approximation based on the mid-point of our initial 2020 Sales Outlook which was withdrawn with the release of our First Quarter Results on May 11, 2020.



### Diverse End Market Exposure with Meaningful Long Term Growth

	Sales Per	formance		
Platform / End Markets	Organic YoY	Sequential Q3 vs. Q2	Near Term Expectations	Long Term Growth Drivers
Defense	▲	1	Performance on pace with initial expectations for 2020	<ul> <li>Defense exposures provide stability and growth opportunities</li> <li>Gaining market share on key defense programs, such as the F-18, the Joint Strike Fighter, the BLACKHAWK Helicopter</li> </ul>
Commercial, Business & General Aviation	$\rightarrow$	1	Headwinds from Commercial Aviation offset by growth in Business & General Aviation	<ul> <li>Breadth of content on a wide range of fixed wing and rotary</li> <li>Continued investment in R&amp;D through the downturn</li> <li>Positioned to capture share from COVID-19 headwinds</li> </ul>
Medical	→	1	COVID-19 resurgence in US resulting in continued deferral of elective procedures	<ul> <li>Aging population</li> <li>Increasing biopharma capital budgets</li> <li>Strong technical advances and product development pipelines</li> </ul>
Industrials			Modest decrease in fourth quarter when compared to third quarter result	<ul> <li>Increasing number of robotics applications</li> <li>Maintenance and replacement of industrial equipment</li> </ul>

### A Focus on Cost

### KAMAN

#### Significant Cost Savings Achieved; Additional Actions Identified

Instituted Cost Savings	~\$50 million of Annualized Savings
<ul> <li>Actions:</li> <li>Execution on G&amp;A Transformation Initiative</li> <li>Workforce reductions</li> <li>Employee furloughs</li> <li>Salary reductions across senior management</li> <li>Reduced discretionary spending</li> </ul> Result: \$26 Million of Savings in 2020; \$42.5 Million Annualized Savings	\$6.0 \$4.5 \$21.0
Additional Actions	\$3.0
<ul> <li>Actions:</li> <li>Adjust production capacity to meet future demand</li> <li>Completion of our G&amp;A Transformation Initiatives</li> </ul>	\$17.0 \$1.5 \$3.0 \$3.0
Result: \$7.5 million of Annualized Savings	Instituted ActionsAdditional ActionsTotal SavingsG&A TransformationAdditional ActionsWorkforce ActionsDiscretionary Spending

### Looking Ahead

### KAMAN

Diverse Mix of Products and End Markets	Strong Balance Sheet and Ample Liquidity	Disciplined Operating Approach	Focus on Health and Safety			
Expanded portfolio of high margin products with diverse end market exposure	Financial strength positions us to manage through the downturn and invest in R&D and growth initiatives	Greater impact to our commercial aerospace business; productivity and efficiency headwinds across organization	Policies and procedures to protect the health & safety of employees and maintain operations			
<ul> <li>~50% Defense</li> <li>~30% Commercial, Business &amp; General Aviation</li> <li>~10% Medical</li> <li>~10% Industrial and Other</li> </ul>	<ul> <li>\$152M of cash available on hand</li> <li>Significant capacity under our \$800M credit facility</li> <li>No debt maturities until 2024</li> </ul>	<ul> <li>Adjusting production needs to meet demand</li> <li>Reduced discretionary spending</li> <li>Salary reductions across our senior management</li> <li>Board reduced retainers 20%</li> </ul>	<ul> <li>Appropriate PPE</li> <li>Temperature checks</li> <li>Shift flexibility</li> <li>Social distancing</li> <li>Segregated workspaces</li> <li>Remote work</li> </ul>			



## **Non-GAAP Reconciliations**

#### **Organic Sales**

Organic Sales is defined as "Net Sales" less sales derived from acquisitions completed during the preceding twelve months. We believe that this measure provides management and investors with a more complete understanding of underlying operating results and trends of established, ongoing operations by excluding the effect of acquisitions, which can obscure underlying trends. We also believe that presenting Organic Sales enables a more direct comparison to other businesses and companies in similar industries. Management recognizes that the term "Organic Sales" may be interpreted differently by other companies and under different circumstances. No other adjustments were made during the three-month and nine-month fiscal periods ended October 2, 2020 and September 27, 2019, respectively. The following table illustrates the calculation of Organic Sales using the GAAP measure, "Net Sales".

		For the Three <b>N</b>	/lonths I	For the Nine Months Ended				
(in thousands)	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019	
Net Sales From Continuing Operations	\$	213,959	\$	182,670	\$	599,171	\$	523,816
Acquisition Sales		19,032		-		60,449		-
Organic Sales	\$	194,927	\$	182,670	\$	538,722	\$	523,816
\$ Change	\$	12,257			\$	14,906		
% Change		6.7%				2.8%		

KAMAN

### **Non-GAAP Reconciliation**

#### **Adjusted EBITDA from Continuing Operations**

Adjusted EBITDA from continuing operations is defined as earnings from continuing operations before interest, taxes, other expense (income), net, depreciation and amortization and certain items that are not indicative of the operating performance of the Company's for the period presented. Adjusted EBITDA from continuing operations differs from earnings from continuing operations, as calculated in accordance with GAAP, in that it excludes interest expense, net, income tax expense, depreciation and amortization, other expense (income), net, non-service pension and post retirement benefit expense (income), and certain items that are not indicative of the operating performance of the Company for the period presented. We have made numerous investments in our business, such as acquisitions and capital expenditures, including facility improvements, new machinery and equipment, improvements to our information technology infrastructure and ERP systems, which we have adjusted for in Adjusted EBITDA from continuing operations also does not give effect to cash used for debt service requirements and thus does not reflect funds available for distributions, reinvestments or other discretionary uses. Management believes Adjusted EBITDA from continuing operations that excludes items that are not indicative of operating performance, such as items that are not indicative of persented as a not reflective of operating performance, such as items that are not indicative of the operating results of the operating performance, such as items that are not indicative of persented as an alternative measure of operating performance as determined in accordance with GAAP. No other adjustments were made during the three-month and nine-month fiscal periods ended October 2, 2020 and September 27, 2019. The following table illustrates the calculation of Adjusted EBITDA from continuing operations, such as signal capital periods ended October 2, 2020 and September 27, 2019. The following table illustrates the calculation of Adjusted EBITDA from cont

KAMAN

10

		For the Three I	nths Ended	For the Nine Months Ended				
(in thousands)		October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019
Net Sales From Continuing Operations	\$	213,959	\$	182,670	\$	599,171	\$	523,816
(Loss) earnings from continuing operations, net of tax	\$	(38,507)	\$	10,130	\$	(39,014)	\$	22,341
Interest Expense, net		5,327		4,058		14,382		14,595
Income Tax Expense		679		2,297		(1,022)		3,244
Non-service pension and Post-Retirement Expense		(4,063)		(99)		(12,188)		(298)
Other expense (income), net		(534)		185		(424)		(367)
Depreciation and Amortization		12,390		6,943		32,204		19,308
Other Adjustments								
Non-cash, non-tax goodwill impairment charge		50,307		-		50,307		-
Restructuring and severance costs		1,541		81		7,820		553
Cost associated with corporate development activities		1,866		2,993		4,332		2,993
Bal Seal acquisition costs		14		-		8,461		-
Expenses associated with Bal Seal purchase accounting		5,703		-		19,465		-
Transition service agreement cost, net of transition service agreement income		1,190		210		3,679		210
Senior Leadership Transition Costs		280				280		
Reversal of prior year accruals in current period		(648)		-		(2,123)		-
Gain on sales of U.K Tooling business		-		-		(493)		-
Adjusted EBITDA from Continuing Operations	\$	35,545	\$	26,798	\$	85,666	\$	62,579
Adjusted EBITDA Margin		16.6%		14.7%		14.3%		11.9%

### **Non-GAAP Reconciliation**



#### Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings Per Share from Continuing Operations

Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations are defined as GAAP "Earnings from Continuing Operations" and "Diluted earnings per share from continuing operations", less items that are not indicative of the operating performance of the business for the periods presented. These items are included in the reconciliation below. Management uses Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations to evaluate performance period over period, to analyze the underlying trends in our business and to assess its performance relative to its competitors. We believe that this information is useful for investors and financial institutions seeking to analyze and compare companies on the basis of operating performance. The following table illustrates the calculation of Adjusted Earnings from Continuing Operations and Adjusted Diluted earnings per share from continuing operations. The following table illustrates the calculation of Adjusted Earnings from Continuing Operations and Adjusted Diluted earnings per share from continuing operations. The following table illustrates the calculation of Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share from Continuing Operations and Adjusted Diluted Earnings per share from continuing operations. Form the "Consolidated Statements of Operations" included in the Company's Form 10-Q filed with the Securities and Exchange Commission on November 4, 2020.

	For the three months ended October 2, 2020				
	Adjustments to	Tax Effect of	Adjustments to	<b>Calculation of</b>	
	Net Earnings,	Adjustments to	Net Earnings,	Adjusted Diluted	
in thousands, expect per share amounts)	Pre Tax	Net Earnings	Net of Tax	Earnings Per Share	
let loss from continuing operations			\$(38,507)	\$(1.39)	
djustments					
Non-cash non-tax goodwill impairment charge	\$50,307	\$ -	\$50,307	\$1.82	
Restructuring and severance costs	1,541	354	1,187	0.04	
Cost associated with corporate development activities	1,866	429	1,437	0.05	
Bal Seal acquisition costs	14	3	11	0.00	
Expenses associated with Bal Seal purchase accounting	5,703	1,280	4,423	0.16	
Transition service agreement cost, net of transition service agreement income	1,190	274	916	0.03	
Senior leadership transition	280	64	216	0.01	
Reversal of employee related tax matter in foreign operations	(648)	-	(648)	(0.02)	
djusted earnings from continuing operations			\$19,342	\$0.70	

Weighted Average Shares Outstanding – Diluted

27,687